Collegium Pharmaceutical, Inc.

NasdaqGS:COLL 株式レポート

時価総額:US$1.0b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Collegium Pharmaceutical 将来の成長

Future 基準チェック /26

Collegium Pharmaceuticalの収益は年間7.2%で減少すると予測されていますが、年間利益は年間15.9%で増加すると予想されています。EPS は年間12.3%で増加すると予想されています。

主要情報

15.9%

収益成長率

12.3%

EPS成長率

Pharmaceuticals 収益成長27.6%
収益成長率-7.2%
将来の株主資本利益率n/a
アナリストカバレッジ

Good

最終更新日07 Jun 2024

今後の成長に関する最新情報

Recent updates

Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly

Jun 05
Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly

Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'

May 13

It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

May 10
It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

Collegium Pharmaceutical Q4: The Beat Goes On

Feb 26

These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

Feb 24
These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Jan 05
There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Nov 12
Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Aug 09
Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Mar 10
Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Oct 18
Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet

Jun 24
Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet

Collegium Pharmaceutical: Oversold And Cheap

Jun 12

Collegium Pharmaceutical: Thoughts After Another Strategic Move

Feb 20

There Is A Reason Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Undemanding

Feb 15
There Is A Reason Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Undemanding

We Think Collegium Pharmaceutical (NASDAQ:COLL) Can Stay On Top Of Its Debt

Oct 30
We Think Collegium Pharmaceutical (NASDAQ:COLL) Can Stay On Top Of Its Debt

業績と収益の成長予測

NasdaqGS:COLL - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/20265741872863465
12/31/20255971543193436
12/31/20245831253513566
3/31/202456793308309N/A
12/31/202356748274275N/A
9/30/20235479266268N/A
6/30/2023537-11235236N/A
3/31/2023525-29176177N/A
12/31/2022464-25123124N/A
9/30/2022362-439394N/A
6/30/2022314-356769N/A
3/31/2022273435658N/A
12/31/202127772102104N/A
9/30/20213261048790N/A
6/30/2021326107102107N/A
3/31/202132142115121N/A
12/31/202031027-28094N/A
9/30/202030818-28687N/A
6/30/20203020-31359N/A
3/31/2020299-13-34130N/A
12/31/2019297-232128N/A
9/30/2019296-114754N/A
6/30/2019293-228190N/A
3/31/2019291-30123131N/A
12/31/2018280-39145169N/A
9/30/2018218-6691114N/A
6/30/2018160-623959N/A
3/31/201890-70-34-14N/A
12/31/201728-75N/A-67N/A
9/30/201719-85N/A-77N/A
6/30/20177-98N/A-84N/A
3/31/20174-102N/A-87N/A
12/31/20162-94N/A-75N/A
9/30/20160-76N/A-61N/A
6/30/2016N/A-59N/A-48N/A
3/31/2016N/A-40N/A-31N/A
12/31/2015N/A-20N/A-22N/A
9/30/2015N/A-15N/A-20N/A
6/30/2015N/A-13N/A-18N/A
3/31/2015N/A-12N/A-16N/A
12/31/2014N/A-21N/A-18N/A

アナリストによる今後の成長予測

収入対貯蓄率: COLLの予測収益成長率 (年間15.9% ) は 貯蓄率 ( 2.4% ) を上回っています。

収益対市場: COLLの収益 ( 15.9% ) はUS市場 ( 14.8% ) よりも速いペースで成長すると予測されています。

高成長収益: COLLの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: COLLの収益は今後 3 年間で減少すると予想されています (年間-7.2% )。

高い収益成長: COLLの収益は今後 3 年間で減少すると予測されています (年間-7.2% )。


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: COLLの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です


成長企業の発掘